Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE), Flexion Therapeutics (FLXN) and Evelo Biosciences (EVLO).
Fate Therapeutics (FATE)
BMO Capital analyst Do Kim assigned a Hold rating to Fate Therapeutics today and set a price target of $80.00. The company’s shares closed last Friday at $78.53.
According to TipRanks.com, Kim is a 5-star analyst with an average return of 18.4% and a 52.2% success rate. Kim covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Checkmate Pharmaceuticals, and Vertex Pharmaceuticals.
Fate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $113.38.
See today’s analyst top recommended stocks >>
Flexion Therapeutics (FLXN)
BMO Capital analyst Gary Nachman assigned a Buy rating to Flexion Therapeutics today and set a price target of $20.00. The company’s shares closed last Friday at $8.28.
According to TipRanks.com, Nachman is a 1-star analyst with an average return of -1.9% and a 44.9% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Bausch Health Companies, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Flexion Therapeutics is a Strong Buy with an average price target of $19.78, a 147.9% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.
Evelo Biosciences (EVLO)
In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on Evelo Biosciences, with a price target of $25.00. The company’s shares closed last Friday at $11.02.
According to TipRanks.com, Luchini is a 3-star analyst with an average return of 7.2% and a 41.7% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Applied Genetic Technologies, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evelo Biosciences with a $17.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
